Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Cells. 2020 Jan 13;9(1):198. doi: 10.3390/cells9010198.

Abstract

The RAS/RAF/MEK/ERK (MAPK) signaling cascade is essential for cell inter- and intra-cellular communication, which regulates fundamental cell functions such as growth, survival, and differentiation. The MAPK pathway also integrates signals from complex intracellular networks in performing cellular functions. Despite the initial discovery of the core elements of the MAPK pathways nearly four decades ago, additional findings continue to make a thorough understanding of the molecular mechanisms involved in the regulation of this pathway challenging. Considerable effort has been focused on the regulation of RAF, especially after the discovery of drug resistance and paradoxical activation upon inhibitor binding to the kinase. RAF activity is regulated by phosphorylation and conformation-dependent regulation, including auto-inhibition and dimerization. In this review, we summarize the recent major findings in the study of the RAS/RAF/MEK/ERK signaling cascade, particularly with respect to the impact on clinical cancer therapy.

Keywords: BRAF(V600E); RAF inhibitors; RAS GTPases, RAF family kinases; Ras/RAF/MEK/ERK signaling; neoplasm; paradoxical activation; protein–protein interactions; synthetic lethal.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors*
  • Mitogen-Activated Protein Kinase Kinases / metabolism
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Signal Transduction / drug effects*
  • raf Kinases / antagonists & inhibitors*
  • raf Kinases / metabolism
  • ras Proteins / antagonists & inhibitors*
  • ras Proteins / metabolism

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • raf Kinases
  • Mitogen-Activated Protein Kinase Kinases
  • ras Proteins